Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Lihua Yang, MDPhD, Xiaoli Ma, MDPhD, Yu-Chen Liu, MSc, Wen Zhao, MDPhD, Lihua Yu, PhD, Maoquan Qin, MDPhD, Guanghua Zhu, MDPhD, Kai Wang, MDPhD, Xiaodong Shi, MD, Zhaoxia Zhang, MD, Jingfu Wang, MD, Yuan Sun, MD, Lujia Dong, MD, Shih-Ting Tsao, MSc, Rui Zhang, MSc, Lung-Ji Chang, PhD

Blood (2017) 130 (Supplement 1): 3335.

https://doi.org/10.1182/blood.V130.Suppl_1.3335.3335

Published: 2017

Journal Articles

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Xun Lai, MD, Jian-Qiong Liu, MD, Lujia Dong, MD, Hong-Mei Ou-Yang, PhD, Zi-Jin Dian, PhD, Jian-Xin Song, PhD, Ya-Xian Jiang, PhD, Xiang-Mei Yao, MD, Xue-Zhong Gu, MD, Xiao-Li Gao, MD, Ya-Yun Wu, MD, Lung-Ji Chang, PhD

Blood (2016) 128 (22): 1633.

https://doi.org/10.1182/blood.V128.22.1633.1633

Published: 2016

Journal Articles

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang, PhD, Lujia Dong, MD, Yu-Chen Liu, MSc, Shih-Ting Tsao, MSc, Ya-Chen Li, PhD, Li Liu, MD, Zhiyong Gao, MD, Xiyou Tan, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, Jing-Bo Wang, Yu-Ming Ying, MD, Le-Ping Zhang, MD, Huyong Zheng, MD PhD, Kai Wang, MD PhD, Xiao-Li Zheng, MD, Heng-Xiang Wang, MD, Xun Lai, MD, Dong Li, MD

Blood (2016) 128 (22): 587.

https://doi.org/10.1182/blood.V128.22.587.587

Published: 2016

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

Journal Articles

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

Hongmei Jing, MD, Lung-Ji Chang, PhD, Mingyi Chen, MD PhD, Fang Bao, MD, Jing Wang, Wenming Wang, Yuanyuan Liu, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Lujia Dong, MD

Blood (2015) 126 (23): 5130.

https://doi.org/10.1182/blood.V126.23.5130.5130

Published: 2015

Journal Articles

Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

Lujia Dong, MD, Lung-Ji Chang, PhD, Zhiyong Gao, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, MD, Jing-Bo Wang, MD, Le-Ping Zhang, MD, Yu-Hong Chen, MD, Hu-Yong Zheng, MD, Ting Liu, Ting Niu, MD PhD, He Huang, MD PhD, Rong Liu, MD, Heng-Xiang Wang, MD, Li Gao, MD, Tong-Hua Yang, MD, Xun Lai, MD

Blood (2015) 126 (23): 3774.

https://doi.org/10.1182/blood.V126.23.3774.3774

Published: 2015

Journal Articles

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Yi Luo, Lung-Ji Chang, PhD, Yongxian Hu, MD, Lujia Dong, Guoqing Wei, He Huang, MD PhD

Blood (2015) 126 (23): 3778.

https://doi.org/10.1182/blood.V126.23.3778.3778

Published: 2015

Journal Articles

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Ting Niu, MD PhD, Lung-Ji Chang, PhD, Jinrong Yang, MD, Yuchen Liu, MSc, Lujia Dong, MD, Wei Wang, PhD, Ting Liu, MD

Blood (2015) 126 (23): 5431.

https://doi.org/10.1182/blood.V126.23.5431.5431

Published: 2015

Journal Articles

HLA Disparity Is Associated with Improved Outcomes in Hematological Malignancies After Family HLA-Mismatched /Haploidentical HCT but Not URD

Lujia Dong, M.D., Zhi-Yong Gao, M.D., Xin-Jian Yu, M.D., Xi-You Tan, M.D., Jin-Hong Liu, M.D., Fengjuan Lu, M.D., Yi Xie, M.D., Lung-Ji Chang, PhD, Ling Zhou, M.D., Wen-Rong Lu, M.D., Can Tong, M.D., Yuan-Ying Zeng, M.D., Shuang Hou, M.D., Na Xu, M.D., Xue Yan, M.S., Dao-Pei Lu, M.D.

Blood (2012) 120 (21): 2014.

https://doi.org/10.1182/blood.V120.21.2014.2014

Published: 2012

Journal Articles

Successful Rescue of Refractory/Recurrent Myelogenous Leukemia by Allogeneic Hematopoietic Cell Transplantation and Prophylactic Immunotherapy.

Jing-Bo Wang, Tong Wu, Wan-Ming Da, Chun-Rong Tong, Xing-Yu Cao, Zhi-Yong Gao, Lujia Dong, Yan-Li Zhao, Yu-Ming Yin, Yuan Sun, Yue Lu, Shu-Quan Ji, Dao-Pei Lu

Blood (2009) 114 (22): 4095.

https://doi.org/10.1182/blood.V114.22.4095.4095

Published: 2009

Journal Articles

Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation by Using Cord Blood as the Third Party Cells.

Dao-Pei Lu, Tong Wu, Zhi-Yong Gao, Jing-Bo Wang, Xing-Yu Cao, Yan-Li Zhao, Lujia Dong, Yu-Ming Yin, Shu-Quan Ji, Wan-Ming Da

Blood (2008) 112 (11): 2211.

https://doi.org/10.1182/blood.V112.11.2211.2211

Published: 2008

Journal Articles

Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy.

Lung-Ji Chang, PhD, Chun-Rong Tong, MD, Jih-Luh Tang, MD PhD, Yoshiki Akatsuka, MD PhD, Shuhong Han, PhD, Yin Liang, MSc, Chi-Cheng Li, MD, Lujia Dong, MD, Tong Wu, MD, Dao-Pei Lu, MD

Blood (2007) 110 (11): 4895.

https://doi.org/10.1182/blood.V110.11.4895.4895

Published: 2007

Journal Articles

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

Dao-Pei Lu, Lujia Dong, Tong Wu, Xiao-Jun Huang, Mei-Jie Zhang, Wei Han, Huan Chen, Dai-Hong Liu, Zhi-Yong Gao, Yu-Hong Chen, Lan-Ping Xu, Yao-Chen Zhang, Han-Yun Ren, Dan Li, Kai-Yan Liu

Blood (2006) 107 (8): 3065–3073.

https://doi.org/10.1182/blood-2005-05-2146

Published: 2006

Journal Articles

Haploidentical Hematopoietic Cell Transplantation (HCT) Compared with Matched HCT from Family Donors: report of 216 cases.

Daopei Lu, Wei Han, Lujia Dong, Xiaojun Huang, Kaiyan Liu, Huan Chen, Lanping Xu, Hanyun Ren, Daihong Liu, Yuhong Chen, Tong Wu, Jin Lu, Zhiyong Gao, Jingbo Wang, Qian Jiang, Yaochen Zhang, Jingzhi Wang

Blood (2004) 104 (11): 5160.

https://doi.org/10.1182/blood.V104.11.5160.5160

Published: 2004

NARROW

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

HLA Disparity Is Associated with Improved Outcomes in Hematological Malignancies After Family HLA-Mismatched /Haploidentical HCT but Not URD

Successful Rescue of Refractory/Recurrent Myelogenous Leukemia by Allogeneic Hematopoietic Cell Transplantation and Prophylactic Immunotherapy.

Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation by Using Cord Blood as the Third Party Cells.

Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy.

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

Haploidentical Hematopoietic Cell Transplantation (HCT) Compared with Matched HCT from Family Donors: report of 216 cases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only